Effect of Colostrum on the Symptoms and Mucosal Permeability in Patients with Irritable Bowel Syndrome: A Randomized Placebo-controlled Study by 諛뺤닔�젙 & 泥쒖옱�씗
istration of bovine colostrum could relieve all symptoms of 
IBS (using several scoring systems to monitor IBS), and could 
lead to a decrease in endotoxin levels in patients with IBS (by 
measuring the endotoxin level before and after administra-
tion). 
This study was a prospective, double-blind, randomized, 
placebo-controlled trial to analyze the efficacy of bovine 
colostrum. Patients with IBS (aged, 18−80 years) were volun-
tarily recruited. They were selected according to the ROME 
III criteria, which was the occurrence of recurrent abdominal 
pain or discomfort for at least 3 days per month in the last 
3 months associated with 2 or more of the following: (1) re-
lieved with defecation; (2) onset associated with a change in 
frequency of stool; (3) onset associated with a change in form 
or appearance of stool.11 Patients were randomly classified 
to either the colostrum or placebo group. A sample of bo-
vine colostrum (15 mL; MuKoBaTM, Seoul, Korea) was orally 
administered once daily before breakfast. All the physical 
characteristics of bovine colostrum (e.g., smell, color, taste, 
volume, and packaging) were indistinguishable from the pla-
cebo (artificial milk).
The 8-week study included a 4-week treatment period and 
a 4-week follow-up observation period without treatment. 
Clinic visits were conducted at weeks 0, 4, and 8, while phone 
interviews were performed weekly. Three scoring systems of 
IBS were used for the evaluation of symptom relief to mea-
sure the primary efficacy of colostrum. The first scoring index 
was assessed by using the IBS Global Improvement Scale 
(GIS) with the patients’ rating their overall satisfaction with 
their IBS treatment on a 7-point Likert scale, ranging from 
“very unsatisfied” to “very satisfied”.12 Data were collected 
weekly by using an interactive voice-response telephone-
based system. The second scoring index used was the Gas-
trointestinal Symptom Rating Scale (GSRS-IBS), which was 
a short and user-friendly instrument with excellent psycho-
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BRIEF COMMUNICATION
Irritable bowel syndrome (IBS) is defined by the presence 
of abdominal discomfort or pain associated with altered bow-
el habits with symptoms of constipation and/or diarrhea.1 
IBS affects up to 16.8% of the general population in Korea.2 
Standard treatment of IBS that primarily aims for symptom 
relief, has not yet been established. The pathogenesis of IBS 
appears to be multifactorial, which involves altered gastro-
intestinal motor function, enhanced perception of visceral 
stimuli, and psychosocial factors. A role of enteric mucosal 
immune activation has been recently suggested.3,4 Endotoxin, 
a component from the outer membrane of gram negative 
bacteria, stimulates various inflammatory mediators, such 
as cytokines (e.g., tumor necrosis factor) and acute phase 
reactants (e.g., CRP). Inflammation leads to elevated blood 
endotoxin levels as a result of increased intestinal permeabil-
ity due to intestinal mucosal damage.5 Patients with IBS have 
elevated endotoxin levels, which proves that IBS is associ-
ated with microscopic inflammation of the enteric mucosa.6 
Colostrum, which is produced by female mammals imme-
diately after giving birth, is a nutrient-rich fluid that contains 
immune, growth, and tissue repair factors.7 Colostrum con-
tains a significant amount of complement components that 
act as natural anti-microbial agents to actively stimulate the 
maturation of an infant’s immune system. Bovine colostrum, 
a raw material for immune milk preparations, can be used to 
treat or prevent infections of the gastrointestinal tract.8-10 The 
objectives of this study were to analyze whether the admin-
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metric properties.13 This questionnaire included the rating 
of 13 problems such as satiety, abdominal pain, diarrhea, 
constipation, and bloating on a 7-point Likert scale ranging 
from 1 (good status) to 7 (bad status). Data were collected 
every 2 weeks. The third scoring index was the assessment of 
the quality of life (QOL), by using the IBS-QOL questionnaire, 
which comprised 34 questions relating to the symptoms of 
IBS before treatment (week 0), at the end of colostrum ad-
ministration (week 4), and at the end of the study (week 8).14 
The third scoring index is the most extensively validated of all 
QOL measures, which has accurate psychometric and meth-
odological qualities.15,16 Endotoxin levels obtained through 
blood sampling at weeks 0, 4, and 8 were used as a secondary 
outcome variable.
A total of 18 patients with IBS were randomly classified 
into the colostrum group (n=9) and placebo group (n=9). Pri-
mary analysis by using the IBS-GIS revealed a slightly higher 
rate of symptom relief in the colostrum group (55.5%) than 
the placebo group (44.4%) at 4 weeks, but this difference was 
not significant. The mean symptom score obtained using the 
GSRS-IBS analysis decreased by 1.3 points (from 4.1 to 2.8) 
in the colostrum group and 1.0 point (from 3.6 to 2.6) in the 
placebo group at 4 weeks, and decreased by 1.7 points (from 
4.1 to 2.4) in the colostrum group and 1.1 points (from 3.6 to 
2.5) in the placebo group at 8 weeks (Fig. 1A). The interval 
change of this score was not statistically different between the 
2 groups at both 4 and 8 weeks. The IBS-QOL analysis, which 
was converted to a 0−100 scale ranging from 0 (poor quality 
of life) to 100 (maximum quality of life), revealed that both 
the groups rather made a little change for the worse. The IBS-
QOL score of the colostrum group diminished by 8.8 points 
at 4 weeks and 9.1 points at 8 weeks, and that of the control 
group diminished by 4.7 points at 4 weeks and 6.3 points at 
8 weeks (Fig. 1B). The overall IBS-QOL score was not statisti-
cally different between the 2 groups.
After 4 weeks (i.e. immediately after treatment), the en-
dotoxin levels of patients in the colostrum group showed 
a decrease in 44.4% (4/9) patients, no interval change in 
11.1% (1/9) patients, and an increase in 44.4% (4/9) patients. 
The endotoxin levels of patients in the placebo group did 
not show any decrease; however, no interval change in the 
endotoxin levels was observed in 33.3% (3/9) patients, and 
an increase in 66.6% (6/9) patients. After 8 weeks (i.e. after 
observation period), the endotoxin levels of patients in the 
colostrum group showed a decrease in 33.3% (3/9) patients, 
no interval change in 44.4% (4/9) patients, and an increase in 
22.2% (2/9) patients. The endotoxin levels of patients in the 
placebo group showed a decrease in 11.1% (1/9) patients, 
no interval change in 33.3% (3/9) patients, and an increase 
in 55.5% (5/9) patients. Although patients in the colostrum 
group appeared to have a greater improvement in the endo-
toxin levels as evaluated using categorical analysis, there was 
no significant difference in the interval change of the calcu-
lated endotoxin value between the 2 groups using a repeated 
analysis of variance test (Fig. 2).
Fig. 1. Comparison of patients in the colostrum and placebo groups using (A) GSRS-IBS and (B) IBS-QOL. GSRS-IBS, gastrointestinal symptom 
rating scale-irritable bowel syndrome; IBS-QOL, irritable bowel syndrome-quality of life.
BA
Fig. 2. Comparison of the changes in the endotoxin level between 
patients in the colostrum and placebo groups. 
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A limitation of this study was the small sample size.
In conclusion, this study showed that colostrum had no 
benefits in relieving symptoms and improving mucosal im-
munity of patients with IBS. The response rate of patients in 
the placebo group is crucial in therapeutic trials conducted to 
evaluate IBS. The placebo response rates have ranged from 
16.0−71.4% with a population-weighted average of 40.2% in 
randomized placebo-controlled trials of patients with IBS.17 
This high placebo response rate could also confirm the lack 
of any significant benefits of colostrum in patients with IBS.18 
Therefore, further large-scale studies to demonstrate the use-
fulness of colostrum are required.
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